Health Notes for Women Only

Self-Study Examination

Instructions: After studying the text answer the following true/false or multiple choice questions.  Remember, there's only one answer to each question.

1. Nonprescription NSAIDs can be recommended to women suffering from either prinary or secondary dysmenorrhea

a) True
b) False

2. The following is not a correct recommendation to a patient:

a) An initial dose of naproxen 440mg con be taken for symptom relief.
b) The dose and type of NSAID can be varied every 3-6 months as needed.
c) NSAIDs should only be taken on an as needed basis.
d) If NSAIDs do not provide relief, the patient should see the physician about prescription therapy (e.g. birth control pills).

3. Which of the following symptoms doses not indicate primary dysmenorrhea?

a) Onset of symptoms at 32 years of age.
b) Symptoms are especially bad on the first day of menses.
c) Maximum does of ketoprofen did not relieve symptoms.
d) None of the above indicate primary dysmenorrhea.
e) A and C

4. According to the article, some clinicians advocate the use of which SSRI for use in breastfeeding?

a) Fluoxetine
b) Sertraline
c) Paroxetine
d) Fluvoxamine
e) All of the above

5. Which of the following are most likely to cause sexual dysfunction in women?

a) Tricyclic antidepressants
b) SSRIs
c) MAO inhibitors
d) Buproprion

6. Menopause and pregnancy are both likely to affect antidepressant pharma-cokinetics.

a) True
b) False

7. There is a window of safety for drug exposure from the first day of the hist menstrual period through.

a) Four days post-conception
b) One week post-conception
c) Two weeks post-conception
d) Three weeks post-conception

8. The following should be asked of a patient concerned about taking a medication while breastfeeding:

a) Dose of the drug
b) Schedule / regimen
c) Duration of therapy
d) Age of the infant
e) All of the above

9. Which of the following is not a reason to refer a patient to the physician for treatment of a vaginal yeast infection?

a) Patient is pregnant
b) Patient is diabetic
c) Patient has had three previous yeast infections
d) Patient had a yeast infection last month
e) All of the above are reasons to refer

10. Which of the following statements is incorrect?

a) Concurrent use of an antifungal agent and contraception foam can decrease the effectiveness of both agents.
b) It is OK to use a sanitary napkin during menses while using a vaginal antifungal product.
c) The use of a condom and a diaphragm should be avoided for 72 hours after itra conazole therapy
d) Tioconozole is the best choice for someone who has had a vaginal yeast infection within the last six months.
e) Both C and D are incorrect.

11. The feature which distinguishes yeast infections from bacterial infections is:

a) Burning with urination
b) Urinary frequency
c) Absence of offensive odor from discharge
d) Itching

12. The most cost-effective pharmacotherapy for preventing and treating osteoporosis in postmenopausal women is:

a) alendronate
b) hormone replacement therapy
c) calcitonin
d) ftuoride
e) etidronate

13. Estimated national drect expenditures for osteoporosis and related fractures, including the cost of hospitalization, surgery, and nursing home care are:

a) 1 million dollars per year
b) 1 billion dollars annually
c) 5 billion dollars annually
d) 10 billion dollars annually
e) none of the above

14. Allof the following are risk factors for coronary artery disease in women, except:

a) smoking
b) diabetes
c) hypertension
d) increased estrogen levels
e) elevated cholesterol

15. All of the following statements are true except:

a) Nitrates are not as effective in reducing the frequency or intensity of anginal symptoms in women as they are in men with chronic stable angina.
b) The long term outcome after percutaneous transluminal coronary angioplasty is better for women than for men.
c) Women are more likely to be referred to cardiac rehabilitation programs than men.
d) A recent study demonstrated an increase in 10 year survival from 60% to 70% in women with coronary artery disease on hormone replacement therapy compared to women with coronary artery disease who were not on hormone replacement therapy.
e) The incidence of coronary artery disease in women increases dramatically after menopause.

16. Contraindications to the use of hormonal contraceptive agents include :

a) current thromboembolic disorders
b) a history of hormone sensitive tumors
c) a desire to become pregnant
d) all of the above

17. Non-contraceptive benefits of oral contraceptives include:

a) protection from ovarian and endometrial cancer
b) decreased risk of rheumatoid arthritis
c) reduced risk of ectoppic pregnancy
d) improved cycle control
e) all of the above

18. The American Cancer Society recommends a baseline mammogram at the age of:

a) 35
b) 50
c) 40
d) 60
e) 30

19. Patients diagnosed with breast cancer are most likely to benefit from chemotherapy if they present as:

a) Post-menopausal, hormone receptor positive, and node-positive
b) Pre-menopausal, hormone receptor negative, and node-negative
c) Post-menoaausd, hormone receptor positive, and node-negative
d) Elderly and hormone receptor positive
e) Pre-menopausd, low risk, and node-negalive

20. Use of paditaxel reawes the patient to be pre-medicated with dexamethosone, cimetidine, and diphenhydramine prior to chemotherapy administration :

a) True
b) False

21. What is the single lost predictable indicator of long-term prognosis?

a) Size of tumor
b) Location of tumor
c) Number of malignant nodes
d) Hormone receptor status
e) Type of tumor

22. At the time of initial diagnosis, what percent of patients will already have advanced stage ovarian cancer?

a) 5-10%
b) 30-40%
c) 50-60%
d) 60-70%
e) 80-90%

23. Which of the chemotherapy regimens is considered first-line therapy for ovarian cancer?

a) Cisplatin + carboplatin
b) Cisplatin + paditaxel
c) Cisplatine + cyclophosphamide
d) Carboplatin + cyclophosphamide
e) Topotecan

24. Which of the following is not a side effect of cisplatin?

a) Neurotoxidty
b) Nephrotoxicity
c) Cardiotoxidty
d) Ololoxicity
e) Nausea and vomiting

25. Which of the following new chemotherapeutic agents is approved for the use as a secondline agent for ovarian cancer?

a) Gemcitabine
b) Docetaxel
c) Topotecan
d) Uposomal Doxurubicin